About
Overview
Leadership
Board of Directors
Sustainability
Science
Atacicept in IgAN
Phase 2b Clinical Data
Phase 3 Clinical Trial
Atacicept in LN
MAU868
Publications
Patients
IgAN
BKV
Careers
Open Positions
Benefits
Values
Employee Spotlights
Investors
Contact
About
Overview
Leadership
Board of Directors
Sustainability
Science
Atacicept in IgAN
Phase 2b Clinical Data
Phase 3 Clinical Trial
Atacicept in LN
MAU868
Publications
Patients
IgAN
BKV
Careers
Open Positions
Benefits
Values
Employee Spotlights
Investors
Contact
Pipeline
R & D
Research and Discovery
Preclinical
Clinical
Marketed
Atacicept
IgAN
Clinical
Phase 3
PMN, FSGS, MCD
Clinical
Phase 2
Potential future autoimmune indications
VT-109
Potential future autoimmune indications
Phase 2
BK virus
IgAN = immunoglobulin A nephropathy
FSGS = focal segmental glomerulosclerosis
MCD = minimal change disease
PMN = primary membranous nephropathy.
Top
